Everybody wants rejuvenating sleep, but for folks with narcolepsy it is difficult to get meaningful rest. Avadel Pharmaceuticals plc (Nasdaq:AVDL) is a biopharmaceutical company that has a drug tentatively approved by the FDA for adults with this condition. Their lead drug product leverages their proprietary drug delivery technology for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Comps: Albireo Pharma, Inc. (Nasdaq:ALBO), Atai Life Sciences N.V. (Nasdaq:ATAI)
When we look to compare Avadel Pharmaceuticals to Albireo Pharma and Atai Life Sciences, we can see that Avadel outperforms both when it comes the cash flow. Moreover, in relation to Albireo Pharma, Avadel Pharmaceuticals has more favorable earnings-per-share ratio and higher profit margins. These same metrics are also comparable to that of Atai Life Sciences. Ultimately, Avadel’s and Atai’s stocks have performed well over the past year, returning 23% and 67% respectively.